Literature DB >> 19001286

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Thomas Elter, Julia Kilp, Peter Borchmann, Holger Schulz, Michael Hallek, Andreas Engert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19001286      PMCID： PMC2625426          DOI： 10.3324/haematol.13379

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Authors:  A Osterborg; M J Dyer; D Bunjes; G A Pangalis; Y Bastion; D Catovsky; H Mellstedt
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

2.  Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

Authors:  Thomas Elter; Peter Borchmann; Holger Schulz; Marcel Reiser; Sven Trelle; Roland Schnell; Markus Jensen; Peter Staib; Timo Schinköthe; Hartmut Stützer; Jürgen Rech; Martin Gramatzki; Walter Aulitzky; Ibrahim Hasan; Andreas Josting; Michael Hallek; Andreas Engert
Journal:  J Clin Oncol       Date:  2005-09-06       Impact factor: 44.544

3.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Authors:  William Wierda; Susan O'Brien; Sijin Wen; Stefan Faderl; Guillermo Garcia-Manero; Deborah Thomas; Kim-Anh Do; Jorge Cortes; Charles Koller; Miloslav Beran; Alessandra Ferrajoli; Francis Giles; Susan Lerner; Maher Albitar; Hagop Kantarjian; Michael Keating
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

4.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

5.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

6.  Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Authors:  Marco Montillo; Alessandra Tedeschi; Sara Miqueleiz; Silvio Veronese; Roberto Cairoli; Liliana Intropido; Francesca Ricci; Anna Colosimo; Barbara Scarpati; Michela Montagna; Michele Nichelatti; Mario Regazzi; Enrica Morra
Journal:  J Clin Oncol       Date:  2006-04-17       Impact factor: 44.544

7.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Authors:  K R Rai; C E Freter; R J Mercier; M R Cooper; B S Mitchell; E A Stadtmauer; P Santábarbara; B Wacker; L Brettman
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

8.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

9.  Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

Authors:  Geoff Hale; Peppy Rebello; Lee R Brettman; Chris Fegan; Ben Kennedy; Eva Kimby; Mike Leach; Jeanette Lundin; Håkan Mellstedt; Paul Moreton; Andy C Rawstron; Herman Waldmann; Anders Osterborg; Peter Hillmen
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

10.  Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

Authors:  D R Mould; A Baumann; J Kuhlmann; M J Keating; S Weitman; P Hillmen; L R Brettman; S Reif; P L Bonate
Journal:  Br J Clin Pharmacol       Date:  2007-05-16       Impact factor: 4.335
View more
  4 in total

1.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

2.  A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

Authors:  Carla Casulo; Julie M Vose; William Y Ho; Brad Kahl; Mark Brunvand; Andre Goy; Yvette Kasamon; Bruce Cheson; Jonathan W Friedberg
Journal:  Clin Immunol       Date:  2014-06-11       Impact factor: 3.969

3.  Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia.

Authors:  Michela Montagna; Marco Montillo; Maria A Avanzini; Carmine Tinelli; Alessandra Tedeschi; Livia Visai; Francesca Ricci; Eleonora Vismara; Enrica Morra; Mario Regazzi
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

Review 4.  Alemtuzumab for patients with chronic lymphocytic leukaemia.

Authors:  Nicole Skoetz; Kathrin Bauer; Thomas Elter; Ina Monsef; Verena Roloff; Michael Hallek; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.